Latest Breaking News On - Molecular therapy oncolytics - Page 2 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses April 9, 2021 GMT Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas. These data provide a clinical proof of concept for Transgene’s double deleted VV cop TK - RR - patented virus backbone: after IV administration, TG6002 reached the tumor, multiplied within tumor cells, and induced the local expression of its payload (the

United statesEmiliano calvoLucie larguierDamien carpentierPhilippe cassierAlain sadounSylvie berrebiChristiane jungelsTransgene euronextKaidre bendjamaVictor morenoBernard dogerCitigate dewe rogersonAmerican association for cancer researchCorporate communicationsEuronext paris